A group of lawmakers introduced a proposal Thursday to establish a program for medicinal use of psilocybin mushrooms.
According to a news release, Senate Bill 219, the Medical Psilocybin Act, would create a program for New Mexicans to receive medicinal treatment for prequalified behavioral health conditions such as major treatment-resistant depression, post-traumatic stress disorder, substance use disorders, end-of-life care and others approved by the Department of Health.
According to the National Institute on Drug Abuse, psilocybin is a chemical found in certain mushrooms, often called “magic mushrooms,” which have historically been used recreationally or in traditional ceremonies. It is also being researched as a clinical treatment for substance use disorders and other mental illnesses.
“As an integrative psychiatry provider in the state of New Mexico I strongly support the need of new tools such as medical psilocybin, to assist the rising number of New Mexicans with mental health needs,” Deborah Thorne, a doctor of medical science and certified integrative psychiatry specialist in Las Cruces, said in a statement. “The Medical Psilocybin Act will provide an equitable, safe and well monitored means of offering this valuable medicine to many while strengthening the ongoing research at UNM.”
The bill would establish an advisory board, treatment equity fund and research fund, as well as remove psilocybin from the Controlled Substances Act to protect “qualified and registered patients, clinicians and producers,” according to a joint news release by the office of the Senate and House Democrats.
If passed, the law states that the program would be available by Dec. 31, 2027.
Cosponsor Sen. Craig Brandt (R-Rio Rancho) said in a statement that he is hopeful this treatment option will benefit his “fellow veterans” who may be dealing with post-traumatic stress disorder or other mental health conditions.
“When we’re facing epidemic levels of depression, anxiety, PTSD, and other debilitating mental health conditions, we owe it to those suffering to explore promising new treatments like psilocybin,” cosponsor Rep. Elizabeth “Liz” Thomson (D-Albuquerque) said in a statement. “By establishing a highly regulated, state-run program, we can provide alternative options to those not responding to traditional treatment, in a safe, controlled environment.”
Sponsors introduced the SB19 on the floor Thursday and will present it in the Senate Tax, Business & Transportation Committee. The bill has not been set for committee as of press time.
